HUP0301211A2 - Vérzéscsillapító hatású vWF-tartalmú készítmény és eljárás annak előállítására - Google Patents

Vérzéscsillapító hatású vWF-tartalmú készítmény és eljárás annak előállítására

Info

Publication number
HUP0301211A2
HUP0301211A2 HU0301211A HUP0301211A HUP0301211A2 HU P0301211 A2 HUP0301211 A2 HU P0301211A2 HU 0301211 A HU0301211 A HU 0301211A HU P0301211 A HUP0301211 A HU P0301211A HU P0301211 A2 HUP0301211 A2 HU P0301211A2
Authority
HU
Hungary
Prior art keywords
vwf
preparation containing
production
fraction
containing vwf
Prior art date
Application number
HU0301211A
Other languages
English (en)
Inventor
Gerhard Gruber
Djuro Josic
Monika Stadler
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octapharma Ag filed Critical Octapharma Ag
Publication of HUP0301211A2 publication Critical patent/HUP0301211A2/hu
Publication of HUP0301211A3 publication Critical patent/HUP0301211A3/hu
Publication of HU225992B1 publication Critical patent/HU225992B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány tárgya eljárás von Willebrand-faktort (vWF) tartalmazóvéralvadásgátló hatású készítmény előállítására emberi vérplazmafrakcióból oly módon, hogy a vWF-t tartalmazó emberi vérplazmafrakciót kromatográfiás úton anioncserélő anyagon tisztítják, amelyanioncserélő csoportokkal oltott polimer struktúrákon (sűrűn elágazópolimer anyagokon) rendelkezik, elválasztva a vWF-t tartalmazófrakciót, majd a kapott frakciót ezután tisztítják gél permeációalkalmazásával tisztított hőstabil vWF-tartalmú készítményt állítvaelő és a készítményt a vírus inaktiválás céljából hőkezelik. Atalálmány tárgyát képezi maga a vWF-t tartalmazó véralvadásgátlóhatású készítmény is. Ó
HU0301211A 2000-04-18 2001-04-04 Haemostatically active preparation containing vwf and method for the production thereof HU225992B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00108430A EP1148063A1 (de) 2000-04-18 2000-04-18 Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
PCT/EP2001/003819 WO2001079260A1 (de) 2000-04-18 2001-04-04 Haemostatisch aktives vwf enthaltendes präparat und verfahren zu seiner herstellung

Publications (3)

Publication Number Publication Date
HUP0301211A2 true HUP0301211A2 (hu) 2003-07-28
HUP0301211A3 HUP0301211A3 (en) 2005-12-28
HU225992B1 HU225992B1 (en) 2008-02-28

Family

ID=8168496

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301211A HU225992B1 (en) 2000-04-18 2001-04-04 Haemostatically active preparation containing vwf and method for the production thereof

Country Status (24)

Country Link
US (2) US7166709B2 (hu)
EP (2) EP1148063A1 (hu)
JP (1) JP4976634B2 (hu)
KR (1) KR100685448B1 (hu)
CN (1) CN100448888C (hu)
AT (1) ATE306494T1 (hu)
AU (2) AU6383501A (hu)
BR (1) BR0110193A (hu)
CA (1) CA2406626C (hu)
CZ (1) CZ303932B6 (hu)
DE (1) DE50107689D1 (hu)
DK (1) DK1274721T3 (hu)
EA (1) EA006209B1 (hu)
EE (1) EE200200595A (hu)
ES (1) ES2247117T3 (hu)
HU (1) HU225992B1 (hu)
IL (2) IL152173A0 (hu)
MX (1) MXPA02010017A (hu)
NO (1) NO324773B1 (hu)
RS (1) RS50835B (hu)
SI (1) SI1274721T1 (hu)
UA (1) UA76714C2 (hu)
WO (1) WO2001079260A1 (hu)
ZA (1) ZA200208396B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
ITLU20070007A1 (it) * 2007-05-07 2008-11-08 Kedrion Spa Processo cromatografico per l'ottenimento di un complesso fviii/vwf con differenti rapporti tra le due proteine da utilizzare nella terapia della emofilia a e nella malattia di von willebrand.
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
BRPI0821474B8 (pt) 2007-12-28 2021-05-25 Baxalta GmbH formulação farmacêutica líquida estável
KR101507718B1 (ko) 2008-06-24 2015-04-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
TWI508735B (zh) 2008-10-21 2015-11-21 巴克斯特國際公司 凍乾的重組ｖｗｆ調配物
IT1396528B1 (it) * 2009-01-19 2012-12-14 Kedrion Spa Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).
CA2801116C (en) * 2010-06-01 2019-02-12 Baxter International Inc. Process for making dry and stable hemostatic compositions
US9371355B2 (en) 2010-09-20 2016-06-21 Octapharma Ag Process for production of fibrinogen
US9488625B2 (en) 2010-12-15 2016-11-08 Baxalta GmbH Purification of factor VIII using a conductivity gradient
US10064406B2 (en) * 2011-01-06 2018-09-04 Cytosorbents Corporation Polymeric sorbent for removal of impurities from whole blood and blood products
CN104321340B (zh) 2012-03-13 2018-11-09 欧克塔医药公司 用于生产纤维蛋白原的改进工艺及其生产的纤维蛋白原
CN104411716B (zh) 2012-04-24 2018-09-07 诺和诺德股份有限公司 适用于治疗血友病的化合物
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
FR2632309B1 (fr) 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
ES2053684T3 (es) 1988-11-05 1994-08-01 Octapharma Ag Procedimiento para preparar un factor antihemofilico, altamente puro, no infeccioso, mediante cromatografia.
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
FR2681867B1 (fr) * 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
DE4204694C3 (de) * 1992-02-01 1995-10-12 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie
JP3133338B2 (ja) * 1992-12-16 2001-02-05 イムノ・アクチエンゲゼルシャフト ウイルス的に安全な生物学的組成物の調製方法
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT404358B (de) * 1997-02-04 1998-11-25 Immuno Ag Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
US6531577B1 (en) * 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
AU6383501A (en) 2001-10-30
CZ20023454A3 (cs) 2003-05-14
BR0110193A (pt) 2003-02-11
MXPA02010017A (es) 2003-04-25
EA200201104A1 (ru) 2003-04-24
US7166709B2 (en) 2007-01-23
HUP0301211A3 (en) 2005-12-28
US7985846B2 (en) 2011-07-26
US20030138913A1 (en) 2003-07-24
EP1274721B1 (de) 2005-10-12
AU2001263835B2 (en) 2005-06-09
CA2406626A1 (en) 2001-10-25
NO20025007D0 (no) 2002-10-17
CN100448888C (zh) 2009-01-07
UA76714C2 (uk) 2006-09-15
ZA200208396B (en) 2004-04-30
ES2247117T3 (es) 2006-03-01
CA2406626C (en) 2012-02-21
ATE306494T1 (de) 2005-10-15
EP1274721A1 (de) 2003-01-15
NO324773B1 (no) 2007-12-10
KR100685448B1 (ko) 2007-02-23
JP2004516231A (ja) 2004-06-03
CN1425024A (zh) 2003-06-18
HU225992B1 (en) 2008-02-28
SI1274721T1 (sl) 2006-04-30
IL152173A (en) 2007-07-24
PL358388A1 (en) 2004-08-09
EP1148063A1 (de) 2001-10-24
DK1274721T3 (da) 2006-02-13
JP4976634B2 (ja) 2012-07-18
IL152173A0 (en) 2003-05-29
CZ303932B6 (cs) 2013-07-03
EE200200595A (et) 2004-04-15
YU78402A (sh) 2006-08-17
RS50835B (sr) 2010-08-31
US20070232791A1 (en) 2007-10-04
KR20030019352A (ko) 2003-03-06
NO20025007L (no) 2002-11-28
EA006209B1 (ru) 2005-10-27
WO2001079260A1 (de) 2001-10-25
DE50107689D1 (de) 2006-02-23

Similar Documents

Publication Publication Date Title
HUP0301211A2 (hu) Vérzéscsillapító hatású vWF-tartalmú készítmény és eljárás annak előállítására
DK0862633T3 (da) VP-antigen af JC-virus
MX9701183A (es) Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones.
KR890006221A (ko) 발열물질의 제거방법
DE69034261D1 (de) Antikörper gegen VLA-4
DK0807178T3 (da) Mycobaktielle proteiner, mikroorganismer producerende samme og anvendelser af nævnte proteiner i vacciner og til påvisning af tuberkulose
PL312712A1 (en) High level expression, purification and repeated creasing of group b(porynowe?) proteins of outer membrane of neisseria meningitidis
DE69535018D1 (de) Papillomavirus vakzine
PT1100468E (pt) Microparticulas com superficies adsorventes, processos de fabrico e utilizacao das mesmas
DK149589D0 (da) Dna-sekvens, dna-vektor, muteret hiv-virusgenom, hiv-vaccine og fremgangsmaade til fremstilling af samme
DE3583941D1 (de) Hohlfasermembran mit selektiver durchlaessigkeit, deren herstellung und verfahren zur scheidung von plasmakomponenten sowie plasmakomponentabscheider.
ATE192165T1 (de) Abtrennung von polymerisiertem und unpolymerisiertem hämoglobin unter verwendung von hydroxyapatit
ATE103982T1 (de) Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
ATE395081T1 (de) Lo-cd2a antikörper und dessen verwendungen zur hemmung von t-zell aktivierung und wachstum
DE69020797D1 (de) Lösung von hochmolekularen Polycarbodiimiden sowie Verfahren zu deren Herstellung.
DE59610633D1 (de) Medikament, insbesondere zur modulation der immunantwort bei der bekämpfung von viren, tumoren, bakterien und parasiten
DE69122240D1 (de) Antigen-wirkende proteine von borrelia burgdorferi
DE69206280D1 (de) Succinimid enthaltende Polymere und von diesen hergestellte Latices.
ES2013808A6 (es) Procedimiento para tratar membranas permeables degradadas y membranasresultantes con propiedades de permeacion restablecidas.
TW362099B (en) Process for recovering a high-purity virus-inactivated factor VIII/von Willebrand factor complex by anion exchanger chromatography
WO1994016085A3 (en) Hybrid proteins having cross-linking and tissue-binding activities
DE59710668D1 (de) Monoklonale antikörper gegen das epitop ypydvpdya, verfahren zu deren herstellung und ihre verwendung
ATE265309T1 (de) Klebstoff-freie verbindungen von polymerbauteilen zur erzeugung von geschlossenen mikro- und nanokanalstrukturen
DE3883777D1 (de) Poröse membran aus hydrophilem polypropylen, verfahren zu deren produktion und gerät zur zerlegung von blutplasma.
Colloquium Summer School on Membrane Science and Technology Lanzhou, Gansu Province, People’s Republic of China August 15-29, 1986

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees